Novel anti-HER2 peptide-conjugated theranostic nanoliposomes combining NaYF4:Yb,Er nanoparticles for NIR-activated bioimaging and chemo-photodynamic therapy against breast cancer-Reference-Cited by-同舟云学术

Novel anti-HER2 peptide-conjugated theranostic nanoliposomes combining NaYF4:Yb,Er nanoparticles for NIR-activated bioimaging and chemo-photodynamic therapy against breast cancer

Published:2019 Issue:43 Volume:11 Page:20598-20613
ISSN:2040-3364
Container-title:Nanoscale
language:en
Short-container-title:Nanoscale

Author:

Panikar Sandeep Surendra¹²³⁴⁵^ORCID,Ramírez-García Gonzalo⁶⁷⁴,Vallejo-Cardona Alba A.⁵⁸⁹¹⁰⁴,Banu Nehla¹¹¹²¹³¹⁴¹⁰,Patrón-Soberano Olga A.¹⁵¹⁶¹⁷¹⁸⁴^ORCID,Cialla-May Dana¹⁹²⁰²¹,Camacho-Villegas Tanya A.⁵⁸⁹¹⁰⁴^ORCID,de la Rosa Elder¹²³⁴^ORCID

Affiliation:

1. Universidad De La Salle Bajio

2. Campus Campestre

3. León

4. Mexico

5. CONACYT – Unidad de Biotecnología Médica y Farmacéutica

6. Cátedras CONACYT – Centro de Investigación en Química Aplicada

7. Saltillo

8. Centro de Investigación y Asistencia en Technologia y Diseño del Estado de Jaliso. 800

9. Av. Normalistas

10. Guadalajara

11. Instituto de Enfermedades Crónico-Degenerativas

12. Departamento de Biología Molecular y Genómica

13. CUCS

14. Universidad de Guadalajara

15. División de Biología Molecular

16. Instituto Potosino de Investigación Científica y Tecnológica

17. Camino a la Presa San José 2055

18. San Luis Potosí

19. Leibniz Institute of Photonic Technology

20. Jena

21. Germany

Abstract

Ligand-targeted multifunctional nanoliposome combining NaYF₄:Yb,Er nanoparticles for NIR-activated bioimaging and chemo-photodynamic therapy against HER2 positive breast cancer.

Funder

Centro de Investigaciones en Optica

Publisher

Royal Society of Chemistry (RSC)

Subject

General Materials Science

Link

http://pubs.rsc.org/en/content/articlepdf/2019/NR/C9NR06535K

Reference60 articles.

1. Near-Infrared-Triggered Azobenzene-Liposome/Upconversion Nanoparticle Hybrid Vesicles for Remotely Controlled Drug Delivery to Overcome Cancer Multidrug Resistance

2. Ligand-targeted liposome design: challenges and fundamental considerations

3. Rethinking cancer nanotheranostics